ELI LILLY Aktie

 

Club holding Lilly stock slumped 1% Tuesday while Novo Nordisk shares jumped nearly 9%....

Eli Lilly anchors Zacks' latest Analyst Blog, with new research highlighting pharma growth drivers alongside global energy and banking insights....

Der dänische Pharmakonzern hatin den USA die Zulassung für eine neue Pille zur Gewichtsreduktion erhalten. Damit verschafft sich das Unternehmen einen Vorteil ‍im Wettlauf mit dem US-Konkurrenten Eli Lilly....

Novo Nordisk won approval to sell a pill version of its blockbuster obesity shot Wegovy in the US, a crucial step in its effort to defend its market share from rival Eli Lilly & Co. Novo will start selling the pill in the US in early January, the company said in a statement Monday. It is approved to help people lose weight or maintain previous weight loss over the long term. Novo's stock has fallen by about half this year amid concern about the Danish drugmaker's ability to compete in the obesity market it pioneered. Today's guests: Thomas Romig, Assenagon, Multi Asset CIO (Source: Bloomberg)...

Relief rally underway in Novo Nordisk after a difficult year for the stock which saw it lose ground to arch-competitor Eli Lilly....

Novo Nordisk darf sein Abnehmedikament Wegovy in den USA künftig als Pille verkaufen. Für den dänischen Pharmakonzern die Chance, wieder gegen den Konkurrenten Eli Lilly aufzuholen. Die Aktionäre jubeln....

Food and Drug Administration's approval hands drugmaker Novo Nordisk an edge in the race to market an obesity pillUS regulators on Monday gave the green light to a pill version of the blockbuster weight-loss drug Wegovy, the first daily oral medication to treat obesity.The US Food and Drug Administration's approval handed drugmaker Novo Nordisk an edge over rival Eli Lilly in the race to market an obesity pill. Lilly's oral drug, orforglipron, is still under review. Continue reading......

Novo Nordisk A/S (NVO.US) has received approval from the US Food and Drug Administration (FDA) for an oral weight loss drug, which will compete with rival Eli Lilly and Company (LLY.US) in the weight loss drug market.Following the approval announcement, Novo Nordisk's stock price rose by 10.56% to USD53.18 in after-hours tra......

LLY's strong GLP-1 demand, international launches and new drug contributions highlight why it leads today's top analyst reports lineup....

Novo Nordisk A/S won approval to sell a pill version of its blockbuster obesity shot Wegovy in the US, a crucial step in its effort to defend its market share from rival Eli Lilly & Co....

NEW CANAAN, Conn., Dec. 22, 2025 /PRNewswire/ -- FlyteHealth, a national leader in integrated cardio-kidney-metabolic care, today announced it will provide self-insured organizations with a new access pathway for obesity management medication from Eli Lilly and Company (Lilly) — supported......

Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects....

OAKVILLE, Ontario--(BUSINESS WIRE)--Harvest Portfolios Group Inc. (“Harvest”) announces the following distributions for Harvest High Income Shares ETFs™ for the month ending December 31, 2025. The distribution will be paid on or about January 6, 2026 to securityholders of record on December 31, 2025 with an ex-dividend date of December 31, 2025. Harvest High Income Shares ETF TSX Ticker Distribution Harvest Eli Lilly High Income Shares ETF LLYH $0.1500 per unit Harvest Eli Lilly High Income Shares ETF (US) LLYH.U $0.1500 per unit Harvest Amazon High Income Shares ETF AMZH $0.1400 per unit Harvest Amazon High Income Shares ETF (US) AMZH.U $0.1400 per unit Harvest Microsoft High Income Shares ETF MSFH $0.1400 per unit Harvest Microsoft High Income Shares ETF (US) MSFH.U $0.1400 per unit Harvest NVIDIA High Income Shares ETF NVDH $0.2000 per unit Harvest NVIDIA High Income Shares ETF (US) NVDH.U $0.1900 per unit Harvest Eli Lilly Enhanced High Income Shares ETF LLHE $0.1650 per unit Harvest Eli Lilly E...

Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...

Neuer Zündstoff für unsere Volltreffer-Empfehlung Abivax: Die französische Zeitung La Lettre berichtet von Übernahmegesprächen zwischen dem Biotechunternehmen und dem US-Pharmariesen Eli Lilly. Spannend: Weitere Interessenten seien ebenfalls im Rennen. Die Übernahmegerüchte um die französische Biotechfirma Abivax haben neue Nahrung erhalten. Wie die gut vernetzte Pariser Wirtschaftszeitung La Lettre berichtet, wird Abivax in Finanz- und Industriekreisen […] The post Abivax: Kommt es zur Übernahmeschlacht? first appeared on sharedeals.de....

Bank of America found names such as Microsoft and Eli Lilly to be among the most pivotal stocks in global portfolios heading into 2026....

Fresh data adds momentum to Lilly's weight loss push...

Dank der Abnehmspritze Wegovy stieg der dänische Pharmakonzern Novo Nordisk fast über Nacht zum wertvollsten Konzern Europas auf. Dann folgte der Absturz. Wie Ex-Champion Novo jetzt an seinem Comeback arbeitet und den US-Konkurrenten Eli Lilly wieder einholen will....

The latest trading day saw Eli Lilly (LLY) settling at $1, representing a +1.45% change from its previous close....

These industry titans have gone in opposite directions this year; is that likely to change?...